13 results about "Cyclooxygenase" patented technology

The invention discloses a benzofuran glycoside compound as well as a separation and extraction method, a pharmaceutical composition and application thereof. The compound 1 is separated from an eupatorium chinense extract. And separating and purifying chemical components of the n-butyl alcohol part of the eupatorium chinense root to obtain the benzofuran compound. The inhibition activity of target cyclooxygenase-2 of inflammatory related diseases of all the separated compounds 1 is tested, and the compounds 1 have good inhibition activity on COX-2 enzyme and have good binding energy with target protein. In addition, the compound also has a good NLRP3-related inhibition effect, can be independently used or combined with other medicines to regulate NLRP3-related proteins, and is used for treating NLRP3-related mediated diseases and / or diseases and preparing medicines for preventing or treating the diseases or diseases. The compound 1 also has a good inhibition effect on acetylcholin esterase, and can be used for treating Alzheimer's disease, myasthenia gravis, Parkinson's disease and other diseases.

The application belongs to the technical field of wound dressings, and discloses a water-based gel dressing with antibacterial and scar prevention effects and a preparation method, wherein 3-fluoro-4-carboxyphenylboronic acid is introduced to graft chitooligosaccharide, a large number of catechol structures in tannic acid solution are combined with the phenylboronic acid bond to form a dynamic boron ester bond, and a network gel structure is formed by responding to the supermolecular forces such as hydrogen bonds, wherein the boron ester bond can be broken in response to the high ROS level of the wound microenvironment and the acidic environment caused by bacterial infection, so as to efficiently release celecoxib, a selective non-steroidal anti-inflammatory drug of cyclooxygenase-2, and the liposome of verteporfin is limited in volume and stays in the dressing for a longer time, so that the sustained and stable release can be maintained in the whole wound healing process, thereby achieving the effects of on-demand inflammation regulation and long-acting mechanical response regulation.

The invention provides an aggregation-induced emission (AIE) ionic probe (E)-4-(2-(5-(4-(diphenylamino) phenyl) thiophene-2-yl) vinyl)-1-(4-sulfanilamide acyl benzyl) quinoline-1-onium hexafluorophosphoric acid (V) salt of a targeted golf apparatus, namely a fluorescent probe TTQ-GA, a preparation method of the fluorescent probe TTQ-GA and application of the fluorescent probe TTQ-GA in the aspect of detection. The benzenesulfonamide group of the probe can be selectively combined with a Golgi apparatus protein cyclooxygenase 2 (COX-2) inhibitor SC-558 to realize Golgi apparatus targeting; due to the hydrophobic triphenylamine part and the hydrophilic quinoline cation part of the probe, the probe has amphipathy; the probe does not emit fluorescence in an aqueous solution, and can emit strong fluorescence when molecular movement is limited and excited, so that no-wash marking of the Golgi apparatus is realized; the probe generates a large amount of ROS under light excitation, promotes local lipid peroxidation increase of Golgi apparatus, and promotes cancer cell apoptosis.

The disclosure provides compounds of Formula 1, and the pharmaceutically acceptable salts thereof. The variables in Formula 1, e.g. X1-X5, A1, A2, and R1-R4 are described herein. Such compounds are useful as prostaglandin transport (PGT) inhibitors. The disclosure further includes pharmaceutical compositions comprising a compound of Formula 1 or salt thereof and methods of using compounds of Formula 1 and salts thereof to treat diseases and disorders mediated, at least in part, by prostaglandin levels or cyclooxygenase activity. Such diseases and disorders include painful and inflammatory conditions.

The application provides a whey protein hydrolysate and application thereof in preparation of anti-inflammatory, antioxidant or allergy relief related products. The preparation method has the advantages of high preparation efficiency, fast speed and sufficient hydrolysis. The whey protein hydrolysate obtained through the preparation method is of excellent quality, rich in nutrition, easy to be absorbed by the human body, and can improve the cyclooxygenase-2 inhibition rate, improve the free radical clearance rate, and relieve the kidney and liver damage caused by the body allergy, and thus has the effects of anti-inflammation, anti-oxidation and allergy relief.

The application discloses a benzofuran glycoside compound, a separation and extraction method thereof, a pharmaceutical composition and application, and the compound 1 is separated from a macleaya cordata extract. A benzofuran compound is obtained by separating and purifying a n-butanol part chemical component of a macleaya cordata root. The inhibitory activity of all separated compounds 1 on a target point cyclooxygenase-2 of an inflammatory related disease is tested, the compound 1 has good inhibitory activity on COX-2 enzyme, and the compound 1 has better binding energy with the target point protein. The compound also has good NLRP3 related inhibitory effect, can be used alone or in combination with other drugs to regulate NLRP3 related proteins, is used for treating NLRP3 related mediated diseases and / or diseases, and is used for preparing drugs for preventing or treating the diseases. The compound 1 also has better inhibitory effect on acetylcholinesterase, and can be used for treating diseases such as Alzheimer's disease, myasthenia gravis and Parkinson's disease.

This invention discloses a 7-O-7' lignan (+) / (–)-7- epi -oryzativol, its preparation method, and its applications belong to the field of pharmaceutical chemistry technology. The 7-O-7' lignan (+) / (–)-7- epi -oryzativol has the structure shown in formula C. This class of compounds was first obtained from Artemisia bulbifera (… Laportea bulbifera The compound was isolated from (+) / (–)-7- epi -oryzativol exhibits significant inhibitory activity against cyclooxygenase-2 (COX-2), and compound (+)-7- epi -oryzativol has a high COX-2 selectivity index and exhibits significant anti-inflammatory effects, making it suitable for use in the preparation of anti-inflammatory drugs.

The present invention provides methods of female contraception, the methods comprising administering an effective amount of a combination of a progesterone receptor agonist and a cyclooxygenase-2 inhibitor in each of two doses, the first dose is administered within about 24 hours before or after a first act of sexual intercourse and the second dose is administered between about 36 hours and about 60 hours after the first dose.

The present disclosure relates to a cosmetic composition containing an extract of Cyperus rotundus extracted using warm microbubbles. The extract inhibits nitric oxide (NO) production and exhibits excellent anti-inflammatory efficacy by inhibiting the expression of interleukin 6 (IL-6), cyclooxygenase-2 (COX-2), interleukin-1β (IL-1β), and tumor necrosis factor-α (TNF-α), which are inflammatory expression factors. In addition, the extract enhances the expression of aquaporin-3 (AQP-3), hyaluronan synthase 2 (HAS-2), claudin-1 (CLDN-1), cadherin 1 (CDH1), filaggrin (FLG), and involucrin (IVL), which are genes related to the skin barrier and moisturizing. Thus, when using the extract for cosmetic products, excellent effects can be exhibited in skin soothing, moisturizing, enhancement of the skin barrier, relief of irritation such as erythema, relief of pruritus, and the like, so the extract can be usefully applied to multi-care products that improve skin conditions.

This invention relates to the field of pharmaceutical technology, providing memantine derivatives, their preparation methods, and their application in the preparation of drugs for treating soluble cyclooxygenase-mediated diseases. The memantine derivatives provided by this invention have typical urea or amide structures. The urea and amide structures serve as the primary pharmacophores of sEH (hydrophobic epoxide hemoglobin). The memantine moiety, as a hydrophobic segment, interacts with the receptor hydrophobically. Molecular docking shows that the memantine moiety, as a hydrophobic segment, interacts with the receptor hydrophobically, particularly when both R1 and R2 are methyl groups, which enhances the van der Waals forces. Therefore, the memantine derivatives provided by this invention exhibit high inhibitory activity against human (HsEH) and murine sEH (MsEH), and can be used as sEH inhibitors in the preparation of drugs for treating soluble cyclooxygenase-mediated diseases, showing broad application prospects.

The application discloses a kind of compositions for regulating oil secretion and preparation method and application thereof;The composition includes the following mass percentage of ingredients: azelate di-glycine potassium 1-5%;APN activity inhibitor 1-5%;Plankton extract 1-4%;Nicotinamide 1-2%;The composition of the application inhibits the activity of type I 5alpha-reductase, cyclooxygenase-2 and aminopeptidase N in sebaceous gland cells, improves keratinization of hair follicle orifice, dredges pores, and regulates water and oil balance, and inhibits sebaceous gland cell activity through multi-pathway synergy, jointly regulates the secretion of oil;It fundamentally inhibits the synthesis and secretion of oil in sebaceous gland cells.The composition of the application is suitable for application in various cosmetics for regulating the secretion of oil on scalp or skin, and has good industrial application prospect.

This invention relates to a novel application of all-trans retinoic acid combined with a cyclooxygenase inhibitor in the treatment of prostate cancer. The all-trans retinoic acid is used to regulate gene expression and metabolic processes in tumor cells, promoting cell differentiation and tumor suppressor signaling pathways. The cyclooxygenase inhibitor is used to inhibit prostaglandin production induced by all-trans retinoic acid treatment. The cyclooxygenase inhibitor includes small molecule compounds that specifically inhibit / antagonize cyclooxygenase, interfering molecules that specifically interfere with cyclooxygenase gene expression, gene-editing reagents that specifically knock out the cyclooxygenase gene, reagents that downregulate / lose the function of cyclooxygenase, or antibodies that specifically bind to cyclooxygenase. The advantages are: it reveals that the combination of all-trans retinoic acid and a cyclooxygenase inhibitor reduces the immunosuppressive microenvironment in the tumor during prostate cancer treatment, thereby enhancing the tumor-suppressive effect and strengthening anti-tumor immunity.